chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 0.58
Sex: F
Vaccine: FLU4
Symptoms: Crying, Generalised erythema, Vomiting
Clinical narrative: Within 1 minute after giving vaccine patient began vomiting multiple times and whole body turned bright red, patient was crying unconsolably. Provider ordered oral BENADRYL which the patient vomited as soon as given so BENADRYL IM was ordered and given. Patients symptoms started to reside and was watched in clinic for an additional 45 minutes.
Age: 82.0
Sex: F
Vaccine: PPV
Symptoms: Injection site erythema, Injection site oedema, Injection site pruritus
Clinical narrative: Pt reports developing pruritis and proximal edema below the injection site on the inner portion of her arm (facing closest to her body) the evening the vaccine was administered. Symptoms began improving the next morning; however, proximal edema remained and was confirmed by pharmacist examination. Pt denied pain or fever on January 5, 2019. Pt was advised to continue monitoring symptoms and seek medical care if symptoms did not improve or worsened. On January 7th, pt's husband reported her symptoms continued to improve. Only mild edema and a spot of erythema above the elbow remained.
Age: 59.0
Sex: F
Vaccine: HEP
Symptoms: Underdose
Clinical narrative: 0.5 ml Pediatric dose was administered instead of 1 ml Adult dose.
Age: 62.0
Sex: M
Vaccine: VARZOS
Symptoms: Limb discomfort, Mobility decreased, Nausea, Pain, Pain in extremity
Clinical narrative: 2 hours post vaccination- vaccinated arm was throbbing and was eventually like lead weight. Later that evening patient was nauseated and vomited. We are now 2 days post vaccination and patient still can't get his arm over his head and he can only move it 2 to 3 inches away from his body. Patient also reported swelling and itching in the hand the evening of the vaccination.
Age: 62.0
Sex: M
Vaccine: VARZOS
Symptoms: Peripheral swelling, Pruritus, Vomiting
Clinical narrative: 2 hours post vaccination- vaccinated arm was throbbing and was eventually like lead weight. Later that evening patient was nauseated and vomited. We are now 2 days post vaccination and patient still can't get his arm over his head and he can only move it 2 to 3 inches away from his body. Patient also reported swelling and itching in the hand the evening of the vaccination.
Age: 16.0
Sex: M
Vaccine: FLU4, MNQ
Symptoms: Amnestic disorder, Hypertonia, Posture abnormal, Somnolence, Staring
Clinical narrative: Upon injecting MCV4 pt became unresponsive, toppled over, no jerking, staring off, generalized and 4 ext. tonic yet breathing, no color changes X less than 10 seconds. Pt. became responsive spontaneously. Was slightly drowsy and amnestic for a few minutes (les than 5 minutes).
Age: 16.0
Sex: M
Vaccine: FLU4, MNQ
Symptoms: Unresponsive to stimuli
Clinical narrative: Upon injecting MCV4 pt became unresponsive, toppled over, no jerking, staring off, generalized and 4 ext. tonic yet breathing, no color changes X less than 10 seconds. Pt. became responsive spontaneously. Was slightly drowsy and amnestic for a few minutes (les than 5 minutes).
Age: 56.0
Sex: M
Vaccine: FLU3
Symptoms: Guillain-Barre syndrome, Nerve conduction studies, Nuclear magnetic resonance imaging
Clinical narrative: Guillain-Barre' Syndrome.
Age: 88.0
Sex: M
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event, Wrong product administered
Clinical narrative: Patient verbally requested a FLU shot. We filled and administered a FLU shot. Patient presented back to pharmacy approx 28min later inquiring which shot he received. He said that he wanted the Pneumococcal shot and not the flu shot since he had already received his flu shot earlier in the season.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Asthenia, Chills, Dysstasia, Fatigue, Gait disturbance
Clinical narrative: I got chills and shivers, was feverish, weak, tired and hard to walk or stand, headache and my whole body hurt inside, very painful on the area where I got the shot and swelling there too.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Headache, Injection site pain, Injection site swelling, Pain, Pyrexia
Clinical narrative: I got chills and shivers, was feverish, weak, tired and hard to walk or stand, headache and my whole body hurt inside, very painful on the area where I got the shot and swelling there too.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Headache, Nausea, Pain
Clinical narrative: Achy for almost 24 hours, nausea, headache.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Abdominal pain upper, Chills, Computerised tomogram abnormal, Diarrhoea, Diverticulitis
Clinical narrative: Prior to the vaccination she was pain free (mild LLQ), no dysuria (mild pressure) no fever. The evening after the shot she had fever, 101, chills, diarrhea and stomach pain. Day 2 she stated she was feeling better and then day3- 10 she developed severe stomach pain, new diverticula and diverticulitis. She was supposed to have surgery on Fistula and the surgery was delayed due to new damage to colon.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Pyrexia
Clinical narrative: Prior to the vaccination she was pain free (mild LLQ), no dysuria (mild pressure) no fever. The evening after the shot she had fever, 101, chills, diarrhea and stomach pain. Day 2 she stated she was feeling better and then day3- 10 she developed severe stomach pain, new diverticula and diverticulitis. She was supposed to have surgery on Fistula and the surgery was delayed due to new damage to colon.
Age: 21.0
Sex: F
Vaccine: MNQ, PPV
Symptoms: Aspiration joint normal, C-reactive protein increased, Chills, Headache, Injection site erythema
Clinical narrative: Within 6 hours the injection site was bright red, hot to the touch and could not move the left shoulder without pain. Took TYLENOL and ibuprofen to relieve a headache, fever, chills, and stiff neck to no avail over 3 days, on day 4 went to ER with a fever.
Age: 21.0
Sex: F
Vaccine: MNQ, PPV
Symptoms: Injection site warmth, Musculoskeletal stiffness, Pain, Pyrexia, Red blood cell sedimentation rate increased
Clinical narrative: Within 6 hours the injection site was bright red, hot to the touch and could not move the left shoulder without pain. Took TYLENOL and ibuprofen to relieve a headache, fever, chills, and stiff neck to no avail over 3 days, on day 4 went to ER with a fever.
Age: 21.0
Sex: F
Vaccine: MNQ, PPV
Symptoms: White blood cell count increased, X-ray normal
Clinical narrative: Within 6 hours the injection site was bright red, hot to the touch and could not move the left shoulder without pain. Took TYLENOL and ibuprofen to relieve a headache, fever, chills, and stiff neck to no avail over 3 days, on day 4 went to ER with a fever.
Age: 34.0
Sex: F
Vaccine: TYP
Symptoms: Abdominal discomfort, Abdominal pain, Myalgia
Clinical narrative: Severe muscle ache across the shoulder and neck area. Gets worse for the 24 hours after the dose and then improves till the next dose. Upset stomach and abdominal cramping started on Day 3 and lasted for 48 hours.
Age: 12.0
Sex: F
Vaccine: HPVX, MNQ, TDAP
Symptoms: Dizziness, Fall, Hypotension, Presyncope, Somnolence
Clinical narrative: 12 yo female BIB dad coming in with vasovagal reaction after IMZ update at 4:30pm. Pt was given HPV #1, MCV4, and Tdap. Pt denied any Adverse reactions to vaccinations in past. Denies allergies to food, meds, or environment, latex. Pt walked with dad down hall to exit when her knees began to buckle and she staggered backwards. Pt fell on her bottom and then her back. Denied any head, neck or back pain. Pt had lightheadedness and felt sleepy after she laid down. BP was low after vaccination and eventually went back to normal after drinking some apple juice and rest. Pt was advised to go to ER for further monitoring and workup if needed. Dad took pt to ER.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site infection
Clinical narrative: Patient stated that the site of injection became infected and was prescribed antibiotics by pcp.
Age: 66.0
Sex: F
Vaccine: FLU3
Symptoms: Immediate post-injection reaction, Myalgia, Neuropathy peripheral, Pain
Clinical narrative: Patient states she had instant pain form flu shot given on 10/09/18. Patient complains of constant ache and musle pain. Patient feels nerve firings in upper arm and shoulder. Patient was seen by Dr on 10/31/2018. Patient called and alterted the pharmacy about this reaction on 01/09/2019.
Age: 1.0
Sex: F
Vaccine: IPV, MMR, PPV, VARCEL
Symptoms: Rash, Rash erythematous, Rash pruritic, Rash vesicular
Clinical narrative: Rash consisting of small red bumps, similar to chicken pox. On 3 separate occasions. Each a week apart. First rash starting on her upper back, lasted about 5 days. Second rash on her legs & 3 dots on her chest 2 on her arm. Lasted 3-5 days. 3rd rash started on her lower abdomen, currently 15 dots on her left side of her torso, 4 on her upper back/ neck. Itchy and slightly raised. Currently on day 2 of her 3rd rash.
Age: 34.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site pain, Pain
Clinical narrative: I got a flu on 12/4/2018 and have experienced throbbing pain radiating from the injection site since that time.
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Erythema, Headache, Myalgia, Pain
Clinical narrative: Vaccine administered on 5th 24 hours later red and warm rash appears appropriately 3 cm below injection site. Rash and swelling and painful to touch approximately 2.5 x 5.0 cm in size. Still persisting after 72 hours. Also post 24 hours had chills, muscle aches and HA for 48 hours. HA still persisting after 72 hours.
Sex: F
Vaccine: VARZOS
Symptoms: Skin warm
Clinical narrative: Vaccine administered on 5th 24 hours later red and warm rash appears appropriately 3 cm below injection site. Rash and swelling and painful to touch approximately 2.5 x 5.0 cm in size. Still persisting after 72 hours. Also post 24 hours had chills, muscle aches and HA for 48 hours. HA still persisting after 72 hours.
Age: 63.0
Sex: M
Vaccine: TDAP
Symptoms: Computerised tomogram, Laboratory test, Loss of consciousness, Seizure, Vomiting
Clinical narrative: Patient was given vaccine at 0840A. At 0845 patient started having generalized seizures for about 2 minutes. He woke up in 2 min, vomited clear yellow liquid 100 ml and became unconscious.
Age: 0.33
Sex: M
Vaccine: DTAPIPVHIB, PNC13, RV5
Symptoms: Injection site rash
Clinical narrative: Developed a rash on thighs 2 days after receiving vaccines (as above).
Age: 0.75
Sex: M
Vaccine: FLU4
Symptoms: Pyrexia, Wheezing
Clinical narrative: Developed fever. Temperature 102.2 degrees F and then wheezing.
Age: 61.0
Sex: M
Vaccine: VARZOS
Symptoms: Headache, Pain
Clinical narrative: Headaches and body aches.
Age: 20.0
Sex: M
Vaccine: MMR, VARCEL
Symptoms: Dizziness, Nausea, Vomiting
Clinical narrative: Severe dizziness. Nausea and vomiting. (Update after 1 day - less N/V, still dizzy).
Sex: F
Vaccine: DTAPIPV, MMRV
Symptoms: Vaccination site swelling
Clinical narrative: Swollen on vaccine site.
Age: 1.25
Sex: F
Vaccine: DTAPIPVHIB, PNC13
Symptoms: Balance disorder, Tremor
Clinical narrative: A few hours after PENTACEL (DTAP/IPV/HIB) and PREVNAR (PCV 13) vaccine had tremor of arms, legs and seemed off balance, resolved in 24 hrs.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Facial pain, Inflammation, Rash, Rash erythematous
Clinical narrative: This spontaneous report as received from a pharmacist refers to a 62 year old female patient with no pertinent medical history, drug allergies and concomitant medication. On 06-APR-2015, the patient was vaccinated subcutaneously with 0,65 ml dose of ZOSTAVAX (lot # K015312 and expiration date 17-DEC-2015). On 07-APR-2015, the patient developed pain in the right side of her face and a red, inflamed rash on the right side of her face into her hair line and scalp while she was on travel. The patient received unspecified medical treatment. On 24-APR-2015, the patient went to an Urgent Care where a physician prescribed her sulfamethoxazole, trimethoprim (BACTRIM) and valacyclovir hydrochloride (VALTREX). On 27-APR-2015, the patient saw her physician who prescribed her pregabalin (LYRICA). Patient's lab diagnostics studies were reported as unspecified. The outcomes of the events were reported as not recovered. The patient sought medical attention (office visit). The relatedness between the events and the ZOSTAVAX therapy was not reported. Additional information has been requested. This is an amended report.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Dizziness, Fatigue, Headache, Influenza like illness, Injection site pain
Clinical narrative: This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 68-year-old female patient who received SHINGRIX for prophylaxis. On 6th August 2018, the patient received the 1st dose of SHINGRIX. On 6th August 2018, less than a day after receiving SHINGRIX, the patient experienced injection site swelling and injection site pain. On 7th August 2018, the patient experienced influenza-like symptoms, headache, fatigue and dizziness. On an unknown date, the outcome of the injection site swelling was unknown and the outcome of the injection site pain, influenza-like symptoms, headache, fatigue and dizziness were recovered/resolved. It was unknown if the reporter considered the injection site swelling, injection site pain, influenza-like symptoms, headache, fatigue and dizziness to be related to SHINGRIX. Additional details were received as follows: On 6th August 2018, by that afternoon of vaccination, the patient presented with injection site was swelling and felt sore. This got progressively worse over the next 2 days. The patient also experienced minor flu type symptoms such as fatigue, dizziness, headachy, and was so tired all she wanted to do was stay in bed. The symptoms were resolved after 2 to 3 days or so.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site swelling
Clinical narrative: This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 68-year-old female patient who received SHINGRIX for prophylaxis. On 6th August 2018, the patient received the 1st dose of SHINGRIX. On 6th August 2018, less than a day after receiving SHINGRIX, the patient experienced injection site swelling and injection site pain. On 7th August 2018, the patient experienced influenza-like symptoms, headache, fatigue and dizziness. On an unknown date, the outcome of the injection site swelling was unknown and the outcome of the injection site pain, influenza-like symptoms, headache, fatigue and dizziness were recovered/resolved. It was unknown if the reporter considered the injection site swelling, injection site pain, influenza-like symptoms, headache, fatigue and dizziness to be related to SHINGRIX. Additional details were received as follows: On 6th August 2018, by that afternoon of vaccination, the patient presented with injection site was swelling and felt sore. This got progressively worse over the next 2 days. The patient also experienced minor flu type symptoms such as fatigue, dizziness, headachy, and was so tired all she wanted to do was stay in bed. The symptoms were resolved after 2 to 3 days or so.
Age: 0.33
Sex: M
Vaccine: RV1, DTAPHEPBIP, HIBV, PNC13, RV1
Symptoms: Hypersensitivity, Urticaria
Clinical narrative: My son's entire head broke out into hives immediately after receiving the vaccine. He had to be given prescription strength antihistamines.
Age: 0.33
Sex: M
Vaccine: RV1, DTAPHEPBIP, HIBV, PNC13, RV1
Symptoms: Immediate post-injection reaction, Urticaria
Clinical narrative: My son's entire head broke out into hives immediately after receiving the vaccine. He had to be given prescription strength antihistamines.
Age: 19.0
Sex: F
Vaccine: HEPAB, HPV9
Symptoms: Erythema, Interchange of vaccine products, Pruritus, Skin warm, Vaccination site swelling
Clinical narrative: Pt presented with redness, itching  and warmth to the touch. Locations of vaccination were raised. Pt denied any other system reactions or breathing complications. Pt denies prior vaccine reactions. Dose #3 of TWINRIX and dose 1 of HPV 9 but prior dose of HPV4 received. Seen by medical director and prescribed medication to assist reaction. Pt informed to report to the ER is any breathing concerns present or if symptoms worsen and immunization is not open.
Age: 28.0
Sex: F
Vaccine: TDAP
Symptoms: Dyspnoea, Exposure during pregnancy, Fatigue, Impaired work ability, Malaise
Clinical narrative: Before I received the shot I wasn't sick and was doing fine with my pregnancy. My pregnancy due date was scheduled for December 28th. After receiving the shot my arm was extremely sore and I felt very exhausted. I was told this is normal. Then I got very sick and went to the doctor on October 29th, 2018. I was told I had a virus and since I was pregnant there wasn't much they could do for me and so I had to stay home. I missed a whole week of work due to how sick I became. I never fully recovered from my sickness and still had a stuffy nose and a hard time breathing by the time I delivered my son. I delivered my son 3 weeks too early. My son is 1 month  and 4 days old now and he doesn't look at me or anyone else, and it seems like he has trouble hearing things as well. You could scream next to his ear and he would sleep through it/not look at you. The hospital said his hearing and eyesight were fine, but it doesn't seem that way. I'm not sure if this is due to the vaccine or not, but it does worry me since he was 3 weeks early and I was sick during the final months of my pregnancy.
Age: 28.0
Sex: F
Vaccine: TDAP
Symptoms: Nasal congestion, Neonatal disorder, Pain in extremity, Premature delivery, Viral infection
Clinical narrative: Before I received the shot I wasn't sick and was doing fine with my pregnancy. My pregnancy due date was scheduled for December 28th. After receiving the shot my arm was extremely sore and I felt very exhausted. I was told this is normal. Then I got very sick and went to the doctor on October 29th, 2018. I was told I had a virus and since I was pregnant there wasn't much they could do for me and so I had to stay home. I missed a whole week of work due to how sick I became. I never fully recovered from my sickness and still had a stuffy nose and a hard time breathing by the time I delivered my son. I delivered my son 3 weeks too early. My son is 1 month  and 4 days old now and he doesn't look at me or anyone else, and it seems like he has trouble hearing things as well. You could scream next to his ear and he would sleep through it/not look at you. The hospital said his hearing and eyesight were fine, but it doesn't seem that way. I'm not sure if this is due to the vaccine or not, but it does worry me since he was 3 weeks early and I was sick during the final months of my pregnancy.
Sex: U
Vaccine: PPV
Symptoms: No adverse event, Product storage error
Clinical narrative: Information has been received from a medical assistant referring to a patient of unknown age and gender. The patient's pertinent medical history, concomitant medication and drug reactions/allergies were not provided. On 13-DEC-2018, the patient was inadvertently vaccinated with a dose of PNEUMOVAX 23 (lot # R025296, expiration date 08-JUN-2020; strength, dose, frequency, route were not reported) for prophylaxis. The reporter reported that shipment of PNEUMOVAX 23 was received on 13-DEC-2018 instead of 12-DEC-2018 and was stored in the refrigerator (manufacturing product shipping issue). It was not viable because it was received too late (product storage error). The vaccines were exposed to temperature excursion of 44 Fahrenheit for 1 hour. The data logger was involved. There was no previous temperature excursion. The outcome of the event was unknown. The causality between PNEUMOVAX 23 and the event was unknown. No adverse effected reported.
Sex: U
Vaccine: HEP, RV5
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a nurse referring to multiple unspecified patients of unknown ages and genders. The patient's medical history and concurrent condition were not reported. On an unknown date, multiple unspecified patients were vaccinated with improperly stored doses of ROTATEQ, lot number N034401 and expiration date of 09-MAY-2019 and RECOMBIVAX HB, lot number R015160 and expiration date of 09-NOV-2020 both for prophylaxis (dose, route of administration and anatomical location were not reported). These vaccines were exposed to temperature excursions of (34.8F) (32 degrees F up to 35 degrees F), with a time frame of 1 hour 9 minutes. There was no previous temperature excursion. A "data logger" was involved. There was no treatment given for the event, no lab diagnostics/studies performed and not seek medical attention. The causality between the event and ROTATEQ and RECOMBIVAX HB was not provided. This is a non-valid case due to the lack of patients' identifiers.
Age: 20.0
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: This spontaneous report was received from a licensed practical nurse regarding a 20-year-old patient of an unknown gender. Information on pertinent medical history and drug reactions/allergies were not reported. On 02-JAN-2019, the patient received PROQUAD (strength, dose, frequency were not reported) lot# R008205 with expiry date of 16-SEP-2019 for prophylaxis (product administered to patient of inappropriate age). The vaccine was reconstituted with diluent (DILUENT MRK INJ). No adverse effects were reported. No product quality complaint (PQC) was involved.
Age: 4.0
Sex: F
Vaccine: MMR, VARCEL
Symptoms: Abdominal pain, Headache, Irritability, Respiration abnormal
Clinical narrative: This spontaneous report was received from a Registerd nurse, referring to a 4 year old female patient. The patient had  none pertinent medical history, concurrent condition, concomitant medications, allergies or drug reactions. On 05-DEC-2018, the patient was vaccinated with VARIVAX lot # R018932, expiration date 02-JUL-2020, subcutaneous (strength, frequency, anatomical site and dose were not provided), and M-M-R II lot # R000551, expiration date 08-JAN-2020 (strength, frequency, dose, route of administration and anatomical site were not reported) both for prophylaxis. Other suspect therapies included sterile diluent (STERILE DILUENT)  subcutaneously (strength, dose, frequency, lot number and expiration date were not reported). On 15-DEC-2018, the patient experienced headache, easy breathing (respiration abnormal), irritability and abdominal pain, reported by her mother on 03-JAN-2018. Also, was reported that the patient sought for medical attention but has not received any treatment  and laboratories or clinical studies were not performed. At the reporting time, the patient has not recovered from the events. The causality assessment between the aforementioned events and VARIVAX, M-M-R II and sterile diluent(STERILE DILUENT) was not reported. This report meets the criteria for a Reporter Concern AEQIR, since the nurse requested a lot check of both vaccines with the results provided within two weeks.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 07-NOV-2012, a healthcare provider administered ZOSTAVAX, (lot# and route unknown) to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries.  In May 2017, the patient was treated by a healthcare provider for shingles.  The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In January 2014, a healthcare provider administered ZOSTAVAX, (lot# and route unknown) to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. In February 2017, the patient was treated by a healthcare provider for shingles.  The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided.  The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 17-NOV-2009, a pharmacist administered ZOSTAVAX, (lot# and route unknown) to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. On or about 15-MAR-2016, the patient was treated by a healthcare provider for shingles.  The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 29-DEC-2014, a pharmacist administered ZOSTAVAX, (lot# and route unknown) to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. In December 2015, the patient was treated by a healthcare provider for shingles.  The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2014, a pharmacist administered ZOSTAVAX, (lot# and route unknown) to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related injuries. In 2015, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. The patient used the ZOSTAVAX vaccine for the permanent prevention of shingles and zoster-related injuries. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider(s) recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 11-SEP-2013, a healthcare provider at a medical center (urgent care facility) administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 27-DEC-2016, the patient was treated by a healthcare provider at a medical center (urgent care facility) for shingles.  The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Causality assessment considered events to be related to the use of ZOSTAVAX. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 15-OCT-2011, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 28-SEP-2016, the patient was treated by physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX vaccine to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 14-NOV-2011, a pharmacist at a pharmacy administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On an unknown date in 2016, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the her injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earning capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2013, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). In 2015, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX vaccine to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 23-FEB-2007, a healthcare provider at a city clinic administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 22-MAY-2017, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the his injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earning capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX vaccine to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On an unknown date in 2010, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). In July 2011, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the her injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earning capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX vaccine to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 10-MAR-2015, a pharmacist at a pharmacy administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 03-APR-2017, the patient was treated by a healthcare provider at a hospital for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the his injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earning capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age.  No information was provided regarding concurrent conditions, medical history, or concomitant medications. On or about 10-JAN-2012, a healthcare provider at a federal health care center administered ZOSTAVAX to the patient to obtain permanent prevention and protection against shingles and zoster-related injuries/conditions (dose, route, and lot # not provided). On or about 11-DEC-2016, the patient was treated by healthcare provider at a community healthcare facility for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries.  As a direct and proximate result of ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was not recovered. Causality assessment was related. Additional information has been requested.